Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease.
作者信息
Helvacı Özant, Akçay Ömer Faruk, Yaşar Emre, Derici Ülver, Güz Galip
机构信息
Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
Department of Nephrology, Etlik City Hospital, Ankara, Turkey.
出版信息
ESC Heart Fail. 2025 Apr;12(2):1490-1491. doi: 10.1002/ehf2.15230. Epub 2025 Jan 26.
Abstract
摘要
相似文献
1
Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease.关于钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）在心力衰竭和慢性肾脏病中未得到充分利用的肾脏病学观点
ESC Heart Fail. 2025 Apr;12(2):1490-1491. doi: 10.1002/ehf2.15230. Epub 2025 Jan 26.
2
Response to the Nephrological perspectives on the underutilization of SGLT2i in heart failure and chronic kidney disease.对心力衰竭和慢性肾脏病中SGLT2i使用不足的肾脏病学观点的回应
ESC Heart Fail. 2025 Apr;12(2):1492-1493. doi: 10.1002/ehf2.15229. Epub 2025 Feb 4.
3
Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study.恩格列净和达格列净用于心力衰竭患者的真实世界数据：RED-HEART研究。
ESC Heart Fail. 2025 Feb;12(1):434-446. doi: 10.1002/ehf2.15049. Epub 2024 Sep 28.
4
Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials.影响钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）对心力衰竭事件疗效的因素：一项基于心血管结局试验的荟萃分析
Cardiovasc Diagn Ther. 2021 Jun;11(3):699-706. doi: 10.21037/cdt-20-984.
5
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.基线肾功能对钠-葡萄糖协同转运蛋白2抑制剂治疗肾脏和心力衰竭结局的影响：一项随机对照试验的系统评价和荟萃分析
Diabetes Obes Metab. 2023 May;25(5):1341-1350. doi: 10.1111/dom.14986. Epub 2023 Feb 14.
6
Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.预测慢性肾脏病合并 2 型糖尿病患者使用 SGLT2 抑制剂治疗后发生心肾并发症和治疗失败的因素。
BMC Med. 2022 Jan 10;20(1):2. doi: 10.1186/s12916-021-02191-2.
7
Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019.2013 - 2019年医疗保险受益人中2型糖尿病合并心力衰竭、动脉粥样硬化性心血管疾病和慢性肾脏病患者在使用钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）和胰高血糖素样肽-1受体激动剂（GLP - 1RAs）方面的种族和民族差异
Diabetologia. 2025 Jan;68(1):94-104. doi: 10.1007/s00125-024-06321-2. Epub 2024 Nov 8.
8
General physicians' perspectives on SGLT2 inhibitors for heart failure.全科医生对 SGLT2 抑制剂治疗心力衰竭的看法。
Intern Med J. 2024 Sep;54(9):1483-1489. doi: 10.1111/imj.16440. Epub 2024 Jul 3.
9
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.钠-葡萄糖共转运蛋白 2 抑制剂治疗射血分数保留的心力衰竭和伴有或不伴有 2 型糖尿病的慢性肾脏病：叙事性综述。
Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.
10
Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病肾病及其他疾病中的应用
Glomerular Dis. 2025 Jan 23;5(1):119-132. doi: 10.1159/000543685. eCollection 2025 Jan-Dec.
本文引用的文献
1
Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study.恩格列净和达格列净用于心力衰竭患者的真实世界数据：RED-HEART研究。
ESC Heart Fail. 2025 Feb;12(1):434-446. doi: 10.1002/ehf2.15049. Epub 2024 Sep 28.
2
Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction.重新认识蛋白尿在心力衰竭中的意义：心脏-肾脏相互作用中新兴的经典指标
ESC Heart Fail. 2024 Dec;11(6):3470-3487. doi: 10.1002/ehf2.14811. Epub 2024 May 9.
3
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
4
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.英国初级医疗中慢性肾脏病患者使用钠-葡萄糖协同转运蛋白2抑制剂指南的实施情况：一项横断面研究
EClinicalMedicine. 2024 Jan 19;68:102426. doi: 10.1016/j.eclinm.2024.102426. eCollection 2024 Feb.
5
Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients.达格列净在血液透析和腹膜透析患者中的药代动力学特征。
Clin J Am Soc Nephrol. 2023 Aug 1;18(8):1051-1058. doi: 10.2215/CJN.0000000000000196. Epub 2023 May 25.
6
Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry.慢性心力衰竭患者肾脏病的患病率和临床特征。来自西班牙心脏肾脏登记处的观察。
Rev Esp Cardiol (Engl Ed). 2024 Jan;77(1):50-59. doi: 10.1016/j.rec.2023.05.003. Epub 2023 May 20.
7
Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.钠-葡萄糖共转运蛋白 2 抑制剂在台湾用于 2 型糖尿病和急性肾损伤的发生率。
JAMA Netw Open. 2023 Feb 1;6(2):e230453. doi: 10.1001/jamanetworkopen.2023.0453.
8
Consensus Recommendations for Sick Day Medication Guidance for People With Diabetes, Kidney, or Cardiovascular Disease: A Modified Delphi Process.《针对糖尿病、肾病或心血管疾病患者的病假用药指导共识建议：改良德尔菲法》。
Am J Kidney Dis. 2023 May;81(5):564-574. doi: 10.1053/j.ajkd.2022.10.012. Epub 2022 Dec 5.
9
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.糖尿病对钠-葡萄糖共转运蛋白 2 抑制剂肾脏结局影响的荟萃分析：大型安慰剂对照试验的协作荟萃分析。
Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6.
10
Kidney and heart failure outcomes associated with SGLT2 inhibitor use.与 SGLT2 抑制剂使用相关的肾脏和心力衰竭结局。
Nat Rev Nephrol. 2022 May;18(5):294-306. doi: 10.1038/s41581-022-00535-6. Epub 2022 Feb 10.
Zotero 插件